Merck Halts Development of Osteoporosis Drug Due to Stroke Risk

  • The company won’t file for regulatory approval of odanacatib
  • Findings will be presented at Bone Mineral Research meeting

Merck & Co. will halt development of an experimental drug to treat osteoporosis called odanacatib after a key study showed that older women taking it were more likely to suffer a stroke.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.